文献速递神经肌肉病神经免疫

Netrin-1受体抗体在胸腺瘤相关神经肌强直伴重症肌无力中的研究

Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.
PubMed 文献 · Neurology · 2017-03-01

该研究在3例胸腺瘤相关神经肌强直伴重症肌无力患者血清中鉴定出Netrin-1受体DCC和UNC5A及Caspr2抗体,并在98例患者和219例对照中评估其临床意义。结果显示Netrin-1受体或Caspr2抗体预测胸腺瘤(p<0.05),共存抗体与Morvan综合征相关(p=0.009),抗体对胸腺瘤诊断特异性100%。

要点

  • Netrin-1受体抗体(DCC、UNC5A)与Caspr2抗体常共存于胸腺瘤相关神经肌强直和重症肌无力患者。
  • Netrin-1受体或Caspr2抗体阳性可预测胸腺瘤(p<0.05)。
  • 共存Caspr2和Netrin-1受体抗体与胸腺瘤、重症肌无力、神经肌强直同时存在及Morvan综合征相关(p=0.009)。

核心结论

  • Netrin-1受体抗体(DCC和UNC5A)与Caspr2抗体常共存,并与神经肌强直和重症肌无力患者的胸腺瘤相关。

研究设计与样本

  • 研究用3例胸腺瘤相关神经肌强直伴重症肌无力患者血清进行免疫沉淀鉴定抗原,并在98例患者和219例对照中评估抗体临床意义。

主要发现

  • 免疫沉淀鉴定出DCC、UNC5A和Caspr2三个靶点。
  • 在指定患者中,9例有Netrin-1受体抗体(其中7例合并Caspr2抗体),5例有孤立Caspr2抗体。
  • 219例对照中仅1例有孤立Caspr2抗体并伴复发性脊髓炎。
  • 在神经肌强直和/或重症肌无力患者中,Netrin-1受体或Caspr2抗体预测胸腺瘤(p<0.05)。
  • 共存Caspr2和Netrin-1受体抗体与胸腺瘤、重症肌无力和神经肌强直同时存在相关,常伴Morvan综合征(p=0.009)。

关键数值与推荐

  • Netrin-1受体抗体识别胸腺瘤的敏感性21.4%,特异性100%(Class III证据)。

临床怎么用

  • 对神经肌强直和/或重症肌无力患者检测Netrin-1受体和Caspr2抗体有助于提示胸腺瘤及Morvan综合征。

局限性

  • 研究证据等级为Class III,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify cell-surface antibodies in patients with neuromyotonia and to describe the main clinical implications. METHODS: Sera of 3 patients with thymoma-associated neuromyotonia and myasthenia gravis were used to immunoprecipitate and characterize neuronal cell-surface antigens using reported techniques. The clinical significance of antibodies against precipitated proteins was assessed with sera of 98 patients (neuromyotonia 46, myasthenia gravis 52, thymoma 42; 33 of them with overlapping syndromes) and 219 controls (other neurologic diseases, cancer, and healthy volunteers). RESULTS: Immunoprecipitation studies identified 3 targets, including the Netrin-1 receptors DCC (deleted in colorectal carcinoma) and UNC5A (uncoordinated-5A) as well as Caspr2 (contactin-associated protein-like 2). Cell-based assays with these antigens showed that among the indicated patients, 9 had antibodies against Netrin-1 receptors (7 with additional Caspr2 antibodies) and 5 had isolated Caspr2 antibodies. Only one of the 219 controls had isolated Caspr2 antibodies with relapsing myelitis episodes. Among patients with neuromyotonia and/or myasthenia gravis, the presence of Netrin-1 receptor or Caspr2 antibodies predicted thymoma (p < 0.05). Coexisting Caspr2 and Netrin-1 receptor antibodies were associated with concurrent thymoma, myasthenia gravis, and neuromyotonia, often with Morvan syndrome (p = 0.009). Expression of DCC, UNC5A, and Caspr2 proteins was demonstrated in paraffin-embedded thymoma samples (3) and normal thymus. CONCLUSIONS: Antibodies against Netrin-1 receptors (DCC and UNC5a) and Caspr2 often coexist and associate with thymoma in patients with neuromyotonia and myasthenia gravis. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that antibodies against Netrin-1 receptors can identify patients with thymoma (sensitivity 21.4%, specificity 100%).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Torres-Vega E, Mancheño N, Cebrián-Silla A, et al. Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology. 2017. PMID: 28251919. doi:10.1212/WNL.0000000000003778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。